University of Cambridge > > rs2099's list > Elucidating molecular mechanisms of neurodegeneration with CRISPR-based functional genomics

Elucidating molecular mechanisms of neurodegeneration with CRISPR-based functional genomics

Add to your list(s) Download to your calendar using vCal

  • UserMartin Kampmann, Department of Biochemistry and Biophysics Institute for Neurodegenerative Diseases University of California, San Francisco, USA World_link
  • ClockTuesday 03 March 2020, 14:00-15:00
  • HouseMRC Laboratory Of Molecular Biology (LMB).

If you have a question about this talk, please contact Ritwick Sawarkar.

Human genes associated with brain-related diseases are being discovered at an accelerating pace. A major challenge is the identification of the mechanisms through which these genes act, and of potential therapeutic strategies. To elucidate such mechanisms in relevant human cell types, we established a CRISPR -based platform for genetic screening in human iPSC-derived neurons, astrocytes and microglia. In an application relevant for Alzheimer’s Disease and other neurodegenerative diseases, we are using this platform to understand cellular mechanisms controlling the aggregation, spreading, and toxicity of the protein tau. Tau aggregates are a hallmark of Alzheimer’s Disease and tauopathies. Mutations in tau are linked to familial neurodegenerative diseases. However, we still lack consensus on the molecular mechanisms by which tau contributes to neurodegeneration. Intriguingly, different types of neurons show selective vulnerability to tau aggregation, suggesting that cellular pathways play a key role in controlling aggregation and resulting toxicity. A systematic understanding of these pathways would enable a mechanistic understanding of the disease processes and point to potential therapeutic targets. Our screens have identified roles for specific cellular pathways, including specific chaperones and co-chaperones, autophagy, mitochondrial function, and some factors with mostly uncharacterized function. We are using biochemistry and cell biology to clarify the mechanisms by which these factors control tau aggregation and toxicity, and to evaluate their potential as therapeutic targets.

This talk is part of the rs2099's list series.

Tell a friend about this talk:

This talk is included in these lists:

Note that ex-directory lists are not shown.


© 2006-2022, University of Cambridge. Contact Us | Help and Documentation | Privacy and Publicity